Daniel Fink
ORCID: 0000-0003-3548-6736
· 32 papers in corpus
diagnostic-accuracy
2012
Epithelial ovarian cancer has the highest mortality rate among gynecological cancers. Altered glycosylation is associated with oncogenic transformation producing tumor-associated carbohydrate antigens. We investigated the potential of natur…
lab-animal
2011
BACKGROUND/AIMS: Endometriosis is a benign but chronic disorder associated with pelvic pain and infertility. Enhanced proliferation and reduced apoptosis susceptibility are characteristics of endometriosis. Cordycepin is a poly(A) polymeras…
lab-animal
2011
OBJECTIVE: To investigate whether the histone deacetylase (HDAC) inhibitor romidepsin down-regulates VEGF (vascular endothelial growth factor) gene expression and abrogates VEGF protein secretion in human epithelial endometriotic cells. DE…
diagnostic-accuracy
2011
OBJECTIVE: About 70% of epithelial ovarian cancer patients (EOC) are diagnosed at advanced stage with a five-year survival rate of only 30%. Whilst CA125 detects peritoneally-spread disease, it has limited sensitivity for early cancers, man…
lab-animal
2010
Romidepsin inhibited HDAC activity, produced acetylation of the histone proteins, up-regulated p21, and down-regulated cyclins B1 and D1, resulting in proliferation inhibition and apoptosis activation in 11z immortalized epithelial endometr…
lab-animal
2008
Despite of several therapeutic options in the treatment of endometriosis, most of them are symptomatically oriented. Histone deacetylase-inhibitors (HDACi) are a novel class of epigenetic acting drugs that inhibit growth and induce apoptosi…
guideline
2008
Recent advance in laparoscopy have changed the surgical approach of endometrial cancer patients. The Swissendos Center, Fribourg, in collaboration with AGO (Groupe de travail pour la gynécologie oncologique) and AGE (groupe de travail pour …